Wardati Mazlan-Kepli1,2, Rachael L Macisaac1, Matthew Walters1, Philip Michael William Bath3, Jesse Dawson1. 1. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, G51 4TF, UK. 2. Pharmacy Department, Serdang Hospital, 43000, Kajang, Selangor, Malaysia. 3. Stroke Trials Unit, University of Nottingham, Nottingham, NG7 2UH, UK.
Abstract
AIMS: Antiplatelet drugs are often discontinued early after ischaemic stroke, either because of poor compliance, complications or withdrawal of care. It is unclear whether this places patients at increased risk of recurrence. We explored the association between cardiovascular event rate and persistence with prescribed antiplatelet drugs. METHODS: We used a matched case-control design using the Virtual International Stroke Trials Archive (VISTA). Cases were patients who had an acute coronary syndrome, recurrent stroke or transient ischaemic attack within 90 days post-stroke and were matched for age ± 10 years and sex with up to four controls. Antiplatelet use was categorized as persistent (used for >3 days and continued up to day 90), early cessation (used antiplatelet <3 days) or stopped/interrupted users (used for >3 days but stopped prior to day 90). These categories were compared in cases and controls using a conditional logistic regression model that adjusted for potential confounders. RESULTS: A total of 970 patients were included, of whom 194 were cases and 776 were matched controls. At 90 days, 10 cases (5.2%) and 58 controls (7.5%) stopped/interrupted their antiplatelet. The risk of cardiovascular event was not different in stopped/interrupted users (adjusted odds ratio 0.70, 95% confidence interval 0.33, 1.48; P = 0.352) and early cessations (adjusted odds ratio 1.04, 95% confidence interval 0.62, 1.74; P = 0.876) when compared to persistent users. CONCLUSION: We found no increased risk in patients who stopped and interrupted antiplatelets early after stroke but the study was limited by a small sample size and further research is needed.
AIMS: Antiplatelet drugs are often discontinued early after ischaemic stroke, either because of poor compliance, complications or withdrawal of care. It is unclear whether this places patients at increased risk of recurrence. We explored the association between cardiovascular event rate and persistence with prescribed antiplatelet drugs. METHODS: We used a matched case-control design using the Virtual International Stroke Trials Archive (VISTA). Cases were patients who had an acute coronary syndrome, recurrent stroke or transient ischaemic attack within 90 days post-stroke and were matched for age ± 10 years and sex with up to four controls. Antiplatelet use was categorized as persistent (used for >3 days and continued up to day 90), early cessation (used antiplatelet <3 days) or stopped/interrupted users (used for >3 days but stopped prior to day 90). These categories were compared in cases and controls using a conditional logistic regression model that adjusted for potential confounders. RESULTS: A total of 970 patients were included, of whom 194 were cases and 776 were matched controls. At 90 days, 10 cases (5.2%) and 58 controls (7.5%) stopped/interrupted their antiplatelet. The risk of cardiovascular event was not different in stopped/interrupted users (adjusted odds ratio 0.70, 95% confidence interval 0.33, 1.48; P = 0.352) and early cessations (adjusted odds ratio 1.04, 95% confidence interval 0.62, 1.74; P = 0.876) when compared to persistent users. CONCLUSION: We found no increased risk in patients who stopped and interrupted antiplatelets early after stroke but the study was limited by a small sample size and further research is needed.
Authors: Richard B Hubbard; Chris J P Smith; Liam Smeeth; Tim W Harrison; Anne E Tattersfield Journal: Am J Respir Crit Care Med Date: 2002-09-25 Impact factor: 21.405
Authors: Anchal Sud; Eva M Kline-Rogers; Kim A Eagle; Jianming Fang; David F Armstrong; Krishna Rangarajan; Richard F Otten; Dana R Stafkey-Mailey; Stephanie D Taylor; Steven R Erickson Journal: Ann Pharmacother Date: 2005-10-04 Impact factor: 3.154
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Joseph P Broderick; Jordan B Bonomo; Brett M Kissela; Jane C Khoury; Charles J Moomaw; Kathleen Alwell; Daniel Woo; Matthew L Flaherty; Pooja Khatri; Opeolu Adeoye; Simona Ferioli; Dawn O Kleindorfer Journal: Stroke Date: 2011-06-30 Impact factor: 7.914
Authors: Philipp Diehl; Christoph Halscheid; Christoph Olivier; Thomas Helbing; Christoph Bode; Martin Moser Journal: Clin Res Cardiol Date: 2011-04-09 Impact factor: 5.460
Authors: A H Abdul-Rahim; R L Fulton; B Frank; T Tatlisumak; M Paciaroni; V Caso; H-C Diener; K R Lees Journal: Eur J Neurol Date: 2014-10-16 Impact factor: 6.089
Authors: Stephen Ph Alexander; John A Peters; Eamonn Kelly; Neil Marrion; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Stephen Ph Alexander; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; O Peter Buneman; William A Catterall; John A Cidlowski; Anthony P Davenport; Doriano Fabbro; Grace Fan; John C McGrath; Michael Spedding; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739